In Brief: Lilly's Zyprexa
Executive Summary
Lilly's Zyprexa: Olanzapine for treatment of schizophrenia "approvable" as of Aug. 30. Post-marketing studies are among the issues to be resolved prior to approval, Lilly says. The NDA was submitted on Sept. 21, 1995. Trial data have suggested that Zyprexa treats both negative and positive symptoms of schizophrenia ("The Pink Sheet" Dec. 18, 1995, T&G-10)...